What is Unintentional non adherence? Introduction: The Hidden Barrier of Unintentional Non-Adherence

Unintentional non-adherence refers to the failure of patients to follow the prescribed treatment regimen due to factors beyond their control. These factors include forgetfulness, confusion about instructions, cognitive impairment, or practical barriers to medication access or administration. It is a significant issue in healthcare, affecting patients with chronic conditions and leading to suboptimal health outcomes. Understanding and addressing unintentional non-adherence is crucial for improving medication adherence and patient care

Medication adherence is critical for managing chronic conditions like hypertension, diabetes, and asthma, yet up to 50% of patients struggle to take their medications as prescribed. While some choose to skip doses intentionally, many miss them unintentionally due to forgetfulness or logistical challenges. This phenomenon, known as unintentional non-adherence, is a major hurdle in healthcare, leading to worse health outcomes and increased costs. The 8-item Morisky Medication Adherence Scale (MMAS-8) has emerged as a powerful tool to identify these barriers, with four key questions pinpointing forgetfulness. In this post, we dive into unintentional non-adherence, explore the MMAS-8’s role, and share actionable solutions to improve adherence.

​What is Unintentional Non-Adherence?
Unintentional non-adherence occurs when patients miss medication doses due to accidental reasons, such as forgetting, being too busy, or facing logistical issues like travel. Unlike intentional non-adherence (e.g., skipping doses due to side effects), unintentional lapses are often tied to memory or routine disruptions. Studies, like one from PLOS One (2017), show that up to 62% of patients report forgetting their medications, making it a leading cause of non-adherence.

The MMAS-8: A Game-Changer for Identifying Unintentional Non-Adherence
The MMAS-8, developed by Dr. Donald E. Morisky, is a validated self-report tool used globally to assess medication adherence. Its eight questions distinguish between intentional and unintentional non-adherence, with four specifically targeting forgetfulness and logistical barriers:

1. Do you sometimes forget to take your medication?
2. When you travel or leave home, do you sometimes forget to bring your medication?
3. Did you take your medication the last time you were supposed to take it?
4. How often do you have difficulty remembering to take all your medications?

These questions, validated in studies like Revista Portuguesa de Cardiologia (2018), form the unintentional non-adherence subscale, helping clinicians identify patients struggling with forgetfulness.

Why Unintentional Non-Adherence Matters
Unintentional non-adherence has serious consequences:
• Health Risks: Missed doses can worsen chronic conditions, leading to complications like heart attacks or asthma exacerbations.
• Economic Impact: Non-adherence costs the U.S. healthcare system $100–$300 billion annually, per a 2012 PMC study.
• Patient Quality of Life: Inconsistent medication use reduces treatment effectiveness, impacting daily functioning.
Understanding and addressing unintentional non-adherence can improve patient outcomes and reduce healthcare costs.

​Validating Forgetfulness: Insights from Academic Research
Academic studies have rigorously validated the MMAS-8’s unintentional non-adherence questions using multiple methods:
• Asthma Study (2017, PLOS One): Compared MMAS-8 responses with pharmacy refill records and patient interviews. Forgetfulness (item 1) was common, but discrepancies with refill data suggested some patients reported it to mask intentional non-adherence.
• Gout Study (2016, Patient Preference and Adherence): Used Medication Possession Ratio (MPR) and patient-reported outcomes to confirm that forgetfulness (items 1, 4, 8) was linked to complex regimens or travel disruptions.
• Psychiatric Study (2014, International Journal of Clinical and Health Psychology): Correlated MMAS-8 with psychological scales, showing that cognitive issues contributed to forgetfulness in psychiatric patients.
• Technology Review (2020, PMC): Found that electronic monitoring (e.g., MEMS) and reminder interventions reduced missed doses by 20% in patients reporting forgetfulness, validating MMAS-8 responses.
These studies confirm that forgetfulness is a real barrier, though sometimes overstated, requiring tailored interventions.

​Strategies to Overcome Unintentional Non-Adherence
Based on research and the MMAS-8’s insights, here are proven strategies to address forgetfulness:
1. Medication Reminders:
• Smartphone Apps: Apps like Medisafe send alerts for dose times, helping patients who forget (item 1).
• Smart Pill Bottles: Devices track openings and send reminders, as validated in the 2020 PMC review.
2. Simplified Regimens:
• Switching to once-daily dosing reduces memory demands, addressing item 8 (difficulty remembering multiple doses).
3. Pill Organizers:
• Weekly pillboxes help patients track doses, especially useful for those forgetting during travel (item 4).
4. Routine Integration:
• Linking medication to daily habits (e.g., brushing teeth) minimizes forgetfulness, as suggested by patient interviews in the 2017 asthma study.
5. Education and Support:
• Clinicians can use MMAS-8 results to discuss barriers and offer solutions, like travel-friendly packaging for item 4.

Challenges in Addressing Unintentional Non-Adherence
Despite progress, challenges remain:
• Self-Report Bias: Patients may over-report forgetfulness to avoid admitting intentional non-adherence, as noted in the 2016 gout study.
• Resource Limitations: Tools like electronic monitors are costly, limiting access in low-resource settings (PMC, 2020).
• Complex Causes: Forgetfulness may stem from cognitive issues, chaotic schedules, or psychological factors, requiring comprehensive assessment.
H2: The Future of Tackling Unintentional Non-Adherence
Emerging technologies and research offer hope:
• AI and Predictive Analytics: Machine learning could predict forgetfulness risk based on MMAS-8 responses, enabling proactive interventions.
• Digital Health Tools: Wearables and smart dispensers are becoming more accessible, building on the 2020 PMC review’s findings.
• Integrated Validation: Future studies should combine cognitive tests, electronic monitoring, and caregiver reports to fully validate forgetfulness, addressing gaps in current research.

​How to Get Started with the MMAS-8
Clinicians and researchers can use the MMAS-8 to identify unintentional non-adherence. To access the scale, visit www.moriskyscale.com for licensing details, as it’s copyrighted by Dr. Morisky. Administering the MMAS-8 during patient visits can pinpoint forgetfulness and guide tailored interventions.
Conclusion
Unintentional non-adherence, driven by forgetfulness and logistical barriers, is a significant challenge in medication management. The MMAS-8’s four questions on unintentional non-adherence (items 1, 4, 5, 8) provide a validated framework to identify these issues, backed by studies in asthma, gout, psychiatric care, and technology reviews. By leveraging reminders, simplified regimens, and patient education, healthcare providers can address forgetfulness and improve outcomes. As research and technology advance, the fight against unintentional non-adherence is gaining ground, offering hope for better chronic disease management.
Call to Action: Are you struggling with medication adherence? Talk to your healthcare provider about the MMAS-8 or try a reminder app today. Share this post to spread awareness about overcoming unintentional non-adherence!